Xiao Zhang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Inflammatory Response

Epstein Barr Virus

Saccharomyces Cerevisiae

Top Venues

Nature communications

Inflammopharmacology

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Ling Zhong, Wanlin Zhang, Hong Liu, Xinyu Zhang, Zeyu Yang, Zhenfu Wen, Ling Chen, Haolin Chen, Yanran Luo, Yanhong Chen, Qisheng Feng, Mu-Sheng Zeng, Qinjian Zhao, Lixin Liu, Claude Krummenacher, Yi-Xin Zeng, Yongming Chen, Xiaoxue Chen, Xiao Zhang
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection. Nature communications 15 (1) (2024)
Ling Zhong, Wanlin Zhang, Hong Liu, Xinyu Zhang, Zeyu Yang, Zhenfu Wen, Ling Chen, Haolin Chen, Yanran Luo, Yanhong Chen, Qisheng Feng, Mu-Sheng Zeng, Qinjian Zhao, Lixin Liu, Claude Krummenacher, Yi-Xin Zeng, Yongming Chen, Xiaoxue Chen, Xiao Zhang
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection. Nature communications 15 (1) (2024)
Ling Zhong, Wanlin Zhang, Hong Liu, Xinyu Zhang, Zeyu Yang, Zhenfu Wen, Ling Chen, Haolin Chen, Yanran Luo, Yanhong Chen, Qisheng Feng, Mu-Sheng Zeng, Qinjian Zhao, Lixin Liu, Claude Krummenacher, Yi-Xin Zeng, Yongming Chen, Xiaoxue Chen, Xiao Zhang
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection. Nature communications 15 (1) (2024)
Hang Han, Guojiang Zhang, Xiao Zhang, Qinjian Zhao
Nrf2-mediated ferroptosis inhibition: a novel approach for managing inflammatory diseases. Inflammopharmacology (2024)
Ling Zhong, Wanlin Zhang, Hong Liu, Xinyu Zhang, Zeyu Yang, Zhenfu Wen, Ling Chen, Haolin Chen, Yanran Luo, Yanhong Chen, Qisheng Feng, Mu-Sheng Zeng, Qinjian Zhao, Lixin Liu, Claude Krummenacher, Yi-Xin Zeng, Yongming Chen, Xiaoxue Chen, Xiao Zhang
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection. Nature communications 15 (1) (2024)
Haiwen Chen, Xiaobing Duan, Xiaohong Deng, Yingping Huang, Xiang Zhou, Shanshan Zhang, Xiao Zhang, Pingjuan Liu, Chaopin Yang, Guojun Liu, Qinqin Ren, Yan Xiong, Bo Zhu, Jiexia Zhang, Tong Xiang
EBV-upregulated B7-H3 inhibits NK cell-mediated antitumor function and contributes to nasopharyngeal carcinoma progression. Cancer immunology research (2023)
Ling Zhong, Claude Krummenacher, Wanlin Zhang, Junping Hong, Qisheng Feng, Yixin Chen, Qinjian Zhao, Mu-Sheng Zeng, Yi-Xin Zeng, Xiaoxue Chen, Xiao Zhang
Urgency and necessity of Epstein-Barr virus prophylactic vaccines. NPJ vaccines 7 (1) (2022)
Ling Zhong, Claude Krummenacher, Wanlin Zhang, Junping Hong, Qisheng Feng, Yixin Chen, Qinjian Zhao, Mu-Sheng Zeng, Yi-Xin Zeng, Xiaoxue Chen, Xiao Zhang
Urgency and necessity of Epstein-Barr virus prophylactic vaccines. NPJ vaccines 7 (1) (2022)
Ling Zhong, Claude Krummenacher, Wanlin Zhang, Junping Hong, Qisheng Feng, Yixin Chen, Qinjian Zhao, Mu-Sheng Zeng, Yi-Xin Zeng, Xiaoxue Chen, Xiao Zhang
Urgency and necessity of Epstein-Barr virus prophylactic vaccines. NPJ vaccines 7 (1) (2022)